Bioventus Inc. Reports Net Loss of $142.8 Million in Second Quarter of 2023

Bioventus Inc.(BVS), a leading medical d evice company specializing in orthobiologic solutions, has reported its financial results for the second quarter of 2023, revealing a net loss of $142.8 million. The company faced a challenging financial period as its revenue for the quarter decreased to $137.1 million compared to $140.3 million in the same period last year.

Net Loss in Q2 2023

During the three months ended July 1, 2023, Bioventus Inc. experienced a net loss of $142.8 million. This figure represents a significant decrease in financial performance compared to the same period in 2022 when the company reported a net loss of $7.3 million.

Revenue Decline to $137.1 Million